Cure My Disease

Don't miss your cure!

 Log in / Sign up

Digital assistant aims to close gaps in hereditary cancer care

NCT ID NCT06914726

Disease control Sponsor: HealthPartners Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial tests a digital tool that helps doctors and patients manage cancer risks linked to hereditary syndromes like BRCA-related breast/ovarian cancer and Lynch syndrome. The tool provides personalized recommendations during primary care visits. Researchers compare care gaps, shared decision-making, and patient confidence between those using the tool and those receiving usual care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Patient-centered clinical decision support (PC-CDS) tool
What this could lead to
If successful, this tool could help people with hereditary cancer syndromes get the right preventive care and make informed decisions about their health.
What could go wrong
This is a behavioral intervention study, not a drug trial. The tool may not change care patterns or improve outcomes as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,488 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The patient must meet all the following inclusion criteria on date of the Index Visit: 1. Aged 18 years or more at index clinical encounter, 2. Existing genetic testing or problem list evidence of HBOC or LS, 3. Index clinical encounter is with a PCC (family practice, general internal medicine, nurse practitioner, or physician assistant) at a randomized primary care clinic during the accrual period, 4. At the time of the index clinical encounter have EITHER (i) Evidence of having HBOC and not up-to- date on selected variant-specific cancer prevention care OR (ii) Evidence of having LS and not up-to-date on selected variant gene-specific cancer prevention care Exclusion Criteria: 1. Diagnosis of dementia, OR 2. Currently receiving active treatment for cancer, OR 3. In long-term care, palliative care, or hospice care.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Genetic variation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Colorectal Neoplasms, Hereditary Nonpolyposis hereditary breast ovarian cancer syndrome hereditary neoplastic syndrome Lynch syndrome ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Genetic variation Hboc syndrome Hereditary breast/ovarian cancer (BRCA1, BRCA2) Hereditary cancer syndromes Lynch syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • HealthPartners Medical Group

    Minneapolis, Minnesota, 55440, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.